Outcomes of highly active antiretroviral therapy in the context of universal access to healthcare: the U.S. Military HIV Natural History Study - sprookjes - yvandenbroek - TriplyDB

Outcomes of highly active antiretroviral therapy in the context of universal access to healthcare: the U.S. Military HIV Natural History Study

Outcomes of highly active antiretroviral therapy in the context of universal access to healthcare: the U.S. Military HIV Natural History Study

http://www.wikidata.org/entity/Q33951598

about

Hepatitis B vaccine antibody response and the risk of clinical AIDS or death Identification of an abbreviated test battery for detection of HIV-associated neurocognitive impairment in an early-managed HIV-infected cohort A comparison of HAART outcomes between the US military HIV Natural History Study (NHS) and HIV Atlanta Veterans Affairs Cohort Study (HAVACS)Combining epidemiologic and biostatistical tools to enhance variable selection in HIV cohort analyses.HIV outcomes in Hepatitis B virus coinfected individuals on HAART The VACS index predicts mortality in a young, healthy HIV population starting highly active antiretroviral therapy.Cumulative viral load and virologic decay patterns after antiretroviral therapy in HIV-infected subjects influence CD4 recovery and AIDS Hepatitis B vaccine responsiveness and clinical outcomes in HIV controllers.Effectiveness of first-line antiretroviral therapy in the IPEC cohort, Rio de Janeiro, Brazil.Recent trends in early stage response to combination antiretroviral therapy in Australia.Long-term CD4+ lymphocyte response following HAART initiation in a U.S. Military prospective cohort.Influence of the timing of antiretroviral therapy on the potential for normalization of immune status in human immunodeficiency virus 1-infected individuals.Virologic outcomes of HAART with concurrent use of cytochrome P450 enzyme-inducing antiepileptics: a retrospective case control study.Elevated CD8 counts during HAART are associated with HIV virologic treatment failure.Antiretroviral therapy initiated soon after HIV diagnosis as standard care: potential to save lives?Association between hepatitis B vaccine antibody response and CD4 reconstitution after initiation of combination antiretroviral therapy in HIV-infected persons.Clinical, demographic and laboratory parameters at HAART initiation associated with decreased post-HAART survival in a U.S. military prospective HIV cohort.Spontaneous virologic suppression in HIV controllers is independent of delayed-type hypersensitivity test responsiveness.D-Dimer Levels before HIV Seroconversion Remain Elevated Even after Viral Suppression and Are Associated with an Increased Risk of Non-AIDS Events.High Initial HIV/AIDS-Related Mortality and -Its Predictors among Patients on Antiretroviral Therapy in the Kagera Region of Tanzania: A Five-Year Retrospective Cohort Study The impact of enzyme-inducing antiepileptic drugs on antiretroviral drug levels: a case-control study.Modelling the impact of antiretroviral therapy on the epidemic of HIV Hospitalizations among HIV controllers and persons with medically controlled HIV in the U.S. Military HIV Natural History Study.Factors associated with HIV viral load "blips" and the relationship between self-reported adherence and efavirenz blood levels on blip occurrence: a case-control study.Virologic and immunologic outcome of HAART in Human Immunodeficiency Virus (HIV)-1 infected patients with and without tuberculosis (TB) and latent TB infection (LTBI) in Addis Ababa, Ethiopia Factors associated with 10 years of continuous viral load suppression on HAART.Early postseroconversion CD4 cell counts independently predict CD4 cell count recovery in HIV-1-postive subjects receiving antiretroviral therapy Results of a 25-year longitudinal analysis of the serologic incidence of syphilis in a cohort of HIV-infected patients with unrestricted access to care.Humoral Antibody Responses to HIV Viral Proteins and to CD4 Among HIV Controllers, Rapid and Typical Progressors in an HIV-Positive Patient Cohort.Delayed-type hypersensitivity (DTH) test anergy does not impact CD4 reconstitution or normalization of DTH responses during antiretroviral therapy Race/ethnicity and HAART initiation in a military HIV infected cohort.Nationally representative prevalence estimates of gay, bisexual, and other men who have sex with men who have served in the U.S. military.Generalized Confidence Intervals and Fiducial Intervals for Some Epidemiological Measures.Place-Based Predictors of HIV Viral Suppression and Durable Suppression Among Men Who Have Sex With Men in New York City.Inference for Surrogate Endpoint Validation in the Binary Case.Virologic suppression among HIV-infected US Air Force members in a highly-structured programme with free access to care.Antiretroviral changes during the first year of therapy.Molecular diversity of HIV-1 and surveillance of transmitted drug resistance variants among treatment Naïve patients, 5 years after active introduction of HAART in Kuala Lumpur, Malaysia.Determinants of incident chronic kidney disease and progression in a cohort of HIV-infected persons with unrestricted access to health care.Tenofovir-Based Highly Active Antiretroviral Therapy Is Associated with Superior CD4 T Cells Repopulation Compared to Zidovudine-Based HAART in HIV 1 Infected Adults.

P2860

Q28730976-C21AE27B-B85C-46B8-8473-1B1AD6625FAA Q30485790-BB173397-98BB-4F92-8489-F92E71DD4259 Q30486127-FA4FEBE2-F595-495E-B9B0-32D06F4700B0 Q31149210-946A8F86-E150-4D6B-8DE5-3CD7BA846AAC Q33665820-237576F8-8F32-4126-8F02-4B22D61AEBB0 Q33881303-5459CC96-6EF4-491C-BBE1-3B60CA74132B Q33916321-7078DB68-A42E-41BC-A655-6650E22CCE31 Q34075566-1911E6F1-4B53-4155-80BA-9F09CAA00633 Q34153838-4E8E9DC3-36C9-406C-9922-85408E560F98 Q34289433-88FCA69A-D808-449E-B3C9-B3A67D20AA52 Q34569335-FFFFA355-EA2E-4DEE-8357-DF3257460D57 Q34666498-57E2FC34-F818-46D7-A68C-8A80D84D8859 Q35057326-B10486AF-D104-4C50-9D06-7B9C1B91F014 Q35213754-8D0AA7B6-602D-426C-AC80-0736AA527CE0 Q35557314-2E594436-EECF-4D27-9D10-0076792D3877 Q35576220-E75DE2FD-624E-4BCB-8767-CD533E242172 Q35873534-709DAF2D-A2FF-427C-819F-4DE7087C7712 Q35959321-2F742536-8FDC-452C-84E4-956F51429F5E Q35992200-B2D948E9-5330-42D9-8F56-56457A12F74E Q36220774-50E9D6F9-64B2-4812-B86B-7F8E1EB8CE40 Q36428784-E4BB8BCA-E98C-4301-9084-44BE22C55B55 Q36486234-11976284-8BCE-47E9-B1C6-83AB4243BBA9 Q36665336-B2C99897-E401-4CA6-8E36-5678D74D0C11 Q36715193-1AFD613C-D704-4D00-9F4E-6F76D9119938 Q37033512-03BF290E-7839-44F7-A7F4-4FBC2F15DFCC Q37118025-2C5545FD-C616-48FB-8D61-B56E410C5910 Q37207042-BD669F69-B43D-40AC-8B1D-FFDCE054C740 Q37355795-0775C2CA-57D8-45E7-A693-8D7BABA0EBD7 Q37523341-C3CE38EA-AF12-4EC8-AC31-BF05F7BB56A3 Q37563963-7EAFDB3E-6AE5-490D-AB75-5429C41DBA00 Q37580896-93A36511-8D7F-45F2-B8C8-29DDE60D83BA Q38649223-1CC9DDA1-1FAA-4F18-B9A0-D6A4730C4C37 Q39670782-837E9E2A-6827-4362-AA0E-161EA595A2BA Q40147303-A850642C-13DC-4DF2-8567-0E12539A0DD8 Q41524577-55C0643A-9A5F-4D67-A062-56710B3D6263 Q41600432-5EFB49E9-23BC-40DD-AF4B-B43422456383 Q41924662-528CE680-E93D-4DAD-87A7-E44E19C514FB Q42262381-F36D223E-3362-4B3F-964B-76B05E68F926 Q46811196-25785086-9BE5-4CA7-977B-3112A8EB8179 Q55169028-2681EFFE-954C-4414-A96E-3DA367CD9F33

P2860

Outcomes of highly active antiretroviral therapy in the context of universal access to healthcare: the U.S. Military HIV Natural History Study

http://www.wikidata.org/entity/Q33951598

description

2010 nî lūn-bûn

@nan

2010 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Outcomes of highly active anti ...... tary HIV Natural History Study

@ast

Outcomes of highly active anti ...... tary HIV Natural History Study

@en

type

label

Outcomes of highly active anti ...... tary HIV Natural History Study

@ast

Outcomes of highly active anti ...... tary HIV Natural History Study

@en

prefLabel

Outcomes of highly active anti ...... tary HIV Natural History Study

@ast

Outcomes of highly active anti ...... tary HIV Natural History Study

@en

P1433

Q33951598-B5E67E6A-B62B-471D-ADAF-323FA39A976B

P1476

Q33951598-DE8CBA5E-E36B-406A-9155-37BBE0DD2D4A

P2093

Q33951598-13DD5DD7-31E3-4275-AFE7-D6F38FCCF807

Q33951598-22309D5C-A746-455C-A1DB-6386BC92A1F0

Q33951598-28738E10-8627-443E-B4A9-FA6751AD120A

Q33951598-9B7BC387-2D0E-4AD7-95D0-2FA392D40C8E

Q33951598-B60D5824-F89A-4C1B-81BC-41929AF2502B

Q33951598-C016B1AA-2A76-4906-A190-D2D036A83B8B

Q33951598-C8A24BDC-5673-42A9-BE01-39D0642E9D5E

Q33951598-CC5A486E-FFE3-4727-B694-068EFCBF8C99

Q33951598-D15C8E33-7A85-4E4E-B0B7-8ACF5B7E5128

Q33951598-E0FC56FF-37DD-4BE7-BECC-D8D86B874B92

P2860

Q33951598-0C9410DA-16A8-480F-91C2-575FAF1CD17F

Q33951598-0CD906DA-3509-46DD-8FB5-E87491FB18EB

Q33951598-13A3C7A2-7CBA-4269-9A51-D3CA2BBC3313

Q33951598-15F6932A-22B8-4201-8D1B-35196AFE0835

Q33951598-17DE0EC2-ABF4-40D2-A579-74FE597F0419

Q33951598-181F8B0D-D343-489A-8605-25BFE6BD85AE

Q33951598-219988DE-C35A-417A-9CEF-8A50483F1A6A

Q33951598-27B0FAF5-C160-441E-95A2-8F7D455D8954

Q33951598-2DE6AEE9-BE31-43EC-853D-21BBFF64C56F

Q33951598-351CA96F-35F5-4041-94CD-CA0937568098

P2888

Q33951598-7121244B-BA0D-4540-B741-233C0414F130

P304

Q33951598-52C12DF0-C784-41D3-882A-C218ADD5FE78

P31

Q33951598-352B9902-FDC6-4884-9D5B-CDD1DB1B06C1

P356

Q33951598-272B0801-7049-4E5C-949A-19BE79A90663

P478

Q33951598-C0088877-BD66-4752-A9D3-100DABBAEC74

P50

Q33951598-8BCFFA8E-725E-401F-B538-AA8349610CC8

Q33951598-9522F868-7866-4ED1-8038-E8BE65F67ACC

Q33951598-AA1E8583-9030-46ED-9ECC-2BAAEA0B9C47

P577

Q33951598-67E14BC6-4A9E-4683-A596-D9E1B8642E4D

P5875

Q33951598-83A3B678-55E5-481D-8518-0E8031F669A5

P6179

Q33951598-9E10DB54-4642-4EC7-BCEE-F5F4A562AEA3

P698

Q33951598-4BCCCF1A-CD82-44DA-9B76-FCA257C2078D

P921

Q33951598-44CC578E-D0D1-4CF5-8AE4-643218505F37

P932

Q33951598-FA3FA837-9D9B-4F02-A3DE-7E909437E8D9

P356

P1433

AIDS Research and Therapy

P1476

Outcomes of highly active anti ...... tary HIV Natural History Study

@en

P2093

Alan Lifson

http://www.w3.org/2001/XMLSchema#string

Amy C Weintrob

http://www.w3.org/2001/XMLSchema#string

Glenn W Wortmann

http://www.w3.org/2001/XMLSchema#string

Greg A Grandits

http://www.w3.org/2001/XMLSchema#string

Helen Chun

http://www.w3.org/2001/XMLSchema#string

Infectious Disease Clinical Research Program HIV Working Group (IDCRP)

http://www.w3.org/2001/XMLSchema#string

Jason F Okulicz

http://www.w3.org/2001/XMLSchema#string

Michael L Landrum

http://www.w3.org/2001/XMLSchema#string

Nancy Crum-Cianflone

http://www.w3.org/2001/XMLSchema#string

Robert J O'Connell

http://www.w3.org/2001/XMLSchema#string

P2860

Progressive resistive exercise interventions for adults living with HIV/AIDS

Efficacy of antiretroviral therapy programs in resource-poor settings: a meta-analysis of the published literature.

Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study.

Estimation of HIV incidence in the United States.

Improved virological outcomes in British Columbia concomitant with decreasing incidence of HIV type 1 drug resistance detection.

Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies.

The fitness training unit in U.S. Army basic combat training: physical fitness, training outcomes, and injuries.

HIV treatment adherence and unprotected sex practices in people receiving antiretroviral therapy.

Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users

Temporal changes in the physical fitness of US Army recruits.

P2888

P304

14

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1742-6405-7-14

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

Vincent C Marconi

Anuradha Ganesan

P577

2010-05-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44635240

http://www.w3.org/2001/XMLSchema#string

P6179

1017363446

http://www.w3.org/2001/XMLSchema#string

P698

20507622

http://www.w3.org/2001/XMLSchema#string

P921

antiretroviral drug

P932

2894737

http://www.w3.org/2001/XMLSchema#string